We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc.는 임상 단계 바이오 제약 회사로, 생명을 위협하는 질환을 가진 환자들을 위한 생물학적 치료제 개발에 주력하고 있습니다. 이 회사의 치료 후보 물질로는 다음과 같습니다. 현재 1상 임상 단계에 있는 INBRX-109는 절제 불가능하거나 전이성인 전형적인 연골육종 치료를 위해 데스 수용체 5(death-receptor 5)를 표적하는 사가(tetravalent) 치료 후보 물질입니다. INBRX-106은 전이성 고형암, 비소세포폐암, 흑색종, 두부 비소세포폐암 세포암종,